Director at Charles River (NYSE: CRL) gets 1,438-share equity grant

Rhea-AI Filing Summary

Andrews Nancy C reported acquisition or exercise transactions in this Form 4 filing.

Charles River Laboratories director Nancy C. Andrews received an equity grant of 1,438 shares of Common Stock, valued at $177.62 per share. This was a compensation-related grant, not an open-market purchase, and increased her direct holdings to 5,402 shares.

The footnote states that the unvested restricted stock units vest on the earlier of May 8, 2027, or the business day before the company’s next annual meeting of shareholders, tying the award to continued service and the company’s governance calendar.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Andrews Nancy C

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,438	$177.62	$255K

Holdings After Transaction: Common Stock — 5,402 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity grant size: 1,438 shares Grant reference price: $177.62 per share Holdings after transaction: 5,402 shares +1 more

4 metrics

Equity grant size 1,438 shares Common Stock grant to director Nancy C. Andrews

Grant reference price $177.62 per share Price per share reported for the 1,438-share grant

Holdings after transaction 5,402 shares Total Common Stock directly held after the grant

Vesting date trigger May 8, 2027 Latest vesting date for unvested restricted stock units

Key Terms

restricted stock units, annual meeting of shareholders, grant, award, or other acquisition

3 terms

restricted stock units financial

"The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual meeting of shareholders regulatory

"…or the business day prior to the Company's next annual meeting of shareholders."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrews Nancy C

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2026		A		1,438(1)	A	$177.62	5,402	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.

	/s/ Nancy C. Andrews	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Nancy C. Andrews report for Charles River Laboratories (CRL)?

Nancy C. Andrews reported receiving a grant of 1,438 shares of Charles River Laboratories Common Stock as compensation. The Form 4 classifies this as a grant or award acquisition rather than an open-market purchase, reflecting routine equity-based director compensation.

Was the Nancy C. Andrews Form 4 for CRL a stock purchase or a grant?

The Form 4 shows a grant, not a market purchase. Andrews acquired 1,438 Common Stock shares through a compensation-related grant at a reference price of $177.62 per share, categorized as a “grant, award, or other acquisition” rather than a discretionary buy in the open market.

How many Charles River (CRL) shares does Nancy C. Andrews hold after this Form 4 transaction?

After the transaction, Nancy C. Andrews directly holds 5,402 shares of Charles River Common Stock. The 1,438-share grant increased her position to this level, providing context that the reported award represents a portion of her overall equity holdings in the company.

When do Nancy C. Andrews’ unvested restricted stock units in CRL vest?

The unvested restricted stock units vest on the earlier of May 8, 2027, or the business day prior to Charles River’s next annual meeting of shareholders. This schedule connects the vesting of the award to both a fixed date and the company’s future shareholder meeting timing.

Does the Nancy C. Andrews Form 4 for CRL indicate any stock sales?

The Form 4 does not report any stock sales. It shows one acquisition transaction classified as a grant or award of 1,438 Common Stock shares, with no corresponding sale, tax-withholding disposition, or derivative exercise activity disclosed in the transaction summary for this filing.